We investigated the roles of insulin and glucagon as mediators of changes in glucose and alanine kinetics during the hypermetabolic response to injury in 10 burn patients by infusing somatostatin with and without insulin replacement. Glucose and alanine kinetics were measured by primed-constant infusions of 6,6-d2-glucose and 13-3Cialanine.
Introduction
The hypermetabolic response to thermal injury is characterized by hyperglycemia and a negative nitrogen balance due to alterations in protein and carbohydrate metabolism (1) (2) (3) . The hyperglycemia results from an increased rate of glucose production (4) , and in order to sustain this elevated rate ofglucose production there is an increased rate of protein breakdown (primarily in skeletal muscle) to provide the extra amino acids needed for gluconeogenesis (5) (6) (7) . Thus, the high rate ofglucose production is directly related to the high rate ofprotein breakdown. Increased morbidity and mortality is associated with the acute protein malnutrition that can result from continual protein loss. Since the administration of exogenous glucose alone or glucose plus amino acids does not reverse the increased gluconeogenesis and nitrogen loss of severe injury and sepsis (7) (8) (9) , a more detailed understanding ofthe mechanism underlying the changes in glucose and protein metabolism is needed, with the hope of ultimately manipulating it to clinical advantage.
Alterations in the concentrations and activities of plasma glucagon and insulin levels in burn injury patients may be responsible for mediating the changes in glucose metabolism (9) (10) (11) (12) . There is general agreement that the elevated plasma glucagon is to some extent responsible for the increased rate of glucose production (9, 10, 12) , whereas the role of insulin as a regulator of hepatic glucose output and as a stimulator of glucose uptake by peripheral tissues may be diminished (4, 9, 13) . Ifthis is true, then lowering glucagon to a lower level should normalize glucose metabolism in burn patients, even if insulin is simultaneously lowered. With this in mind, Wolfe and Burke (4) infused somatostatin to inhibit the pancreatic release of glucagon and insulin in burned patients for 30 min. This procedure caused a significant reduction in the rate of glucose production. There was, however, a decreased clearance of glucose that was significantly correlated with the reduction in insulin concentration. When insulin was maintained at the basal level in one patient by reinfusion, the reduction in glucose production was not accompanied by a fall in glucose clearance, which suggests that basal insulin was effective in stimulating glucose clearance (14) . The results of this study in one patient suggested that by selectively lowering glucagon concentration while maintaining basal insulin constant, it may be possible to reduce gluconeogenesis and maintain a normal glucose uptake (14) .
Since definitive conclusions cannot be made from a onepatient study, we have used tracer techniques to further investigate the response of glucose and alanine kinetics to the manipulation of glucagon and insulin concentrations with somatostatin in 10 severely burned patients. We have compared the response to the simultaneous lowering of insulin and glucagon concentration with the response to selectively lowering only the glucagon concentration. It was our hypothesis that the latter procedure would suppress gluconeogenesis and thereby indirectly reduce the rate of net protein catabolism; and that the comparison of the response to somatostatin infusion with and without insulin replacement would establish the role of the basal insulin concentration in stimulating glucose uptake and suppressing glucose production. Alanine flux was measured because its release is markedly increased from peripheral tissues in severe injury (6) In general, patients were cared for in private rooms with independently adjustable thermostats. The ambient temperature was selected in order to maintain the patient's rectal temperature at no less than 37.50C. Patients with rectal temperatures less than 37.50C had their room's temperature increased until rectal temperature was above this minimum.
Febrile patients (with rectal temperatures >390C) were treated with 1,300 mg acetaminophen or 1,300 mg aspirin. At the time ofstudy all patients had rectal temperatures within the normal range (Table I) , hence room temperature was not altered and no patient was given aspirin or acet-1. Abbreviations used in this paper: TBSA, total body surface area.
aminophen during the course of a study. Patients received nutrition either by mouth or gastric intubation and parenterally to reach their prescribed amount of nutrients. Caloric requirements were estimated as being 25 X body wt (kg) + (40 X percent TBSB) kcals, of which -60% was provided by carbohydrates.
The experimental protocol was approved by The University ofTexas Medical Branch Institutional Review Board. Before their participation, the nature, purpose, and risks of the study were explained in detail to all patients and/or relatives in the presence of a patient advocate, and informed consent was obtained.
Materials. The isotopes infused as tracers in this study were Somatostatin was obtained from Bachem (Torrance, CA) and dissolved in sterile normal saline for infusion. Insulin for infusion was prepared from a stock solution (1 mU/ml of25% ofhuman serum albumin solution) by dilution with normal saline.
Experimental design. Studies were performed in the postabsorptive state. Patients receiving total parenteral nutrition had all nutrition withheld for at least 6 h before the study. However, patients receiving oral/ gastric nutrition were fasted for a full 8 h before study. In all patients 0.45% saline was substituted for the enteral or parenteral alimentation to maintain a comparable fluid delivery rate and a normal state of hydration. At the time of study all patients had an arterial line and central venous line already in place for therapeutic purposes. All solutions were infused through the existing central venous line and blood samples were drawn from the arterial line.
The study consisted of two different experimental protocols ( Fig. 1) and patients from the study population, regardless of their clinical treatment (conservative or early excision), were randomly assigned to either protocol. All the experiments performed in both protocols involved the primed-constant infusion of the isotopes 6,6-d2-glucose and ['3Cjalanine.
Protocol 1. In this protocol six studies were performed in six patients (three excised, three conservative), from day 5 to day 11 postburn. The aim ofthis protocol was to measure the basal rates ofglucose production and alanine flux and to assess the response to an acute and simultaneous suppression of insulin and glucagon release induced by the administration of somatostatin. The response of the basal plasma amino acid profile, cortisol, and human growth hormone levels was also assessed.
A primed-constant infusion of 6,6-d2-glucose (infusion rate of 0.034 mg/kg-' . min-', prime of 2.72 mg/kg) and [3-'3C]alanine (infusion rate, 0.15 zmol/kg-' * min-'; prime, 15 umol/kg) was started and maintained throughout a 4.5-h study period (Fig. 1) . After 1.5 h of only isotope infusion (the basal period), a constant infusion ofsomatostatin was started at the rate of 0.15 ug/kg-' * min-' and maintained for the remaining 3 h ofthe study without interrupting the isotope infusion. A Harvard Model 2716 Syringe Infusion Pump (Harvard Apparatus Co., S. Natick, MA) was used for both infusions. During the somatostatin infusion the plasma glucose level ofthe patient was closely monitored by measuring the concentration on 0.25-ml samples drawn every 10 min using a Glucose Analyzer 2 (Beckman Instruments, Inc., Fullerton, CA.).
A 10-ml blood sample was drawn before the isotope infusion started and at 10-min intervals during the last 30 min ofthe basal period. Samples were also drawn throughout the 3 h of somatostatin infusion at 20-min and then 30-min intervals ( Fig. 1) .
Protocol 2. Six infusions were performed in five patients, with one patient being studied twice. However, data from only one of the two studies in that patient were included in the results of this protocol (n = 5).
The aim of this protocol was to measure the basal rates of glucose production and alanine flux and to assess their response to a selective reduction of glucagon concentration by maintaining basal insulin level constant during the somatostatin administration period. The responses of the basal plasma amino acid profile, cortisol and human growth hormone were also assessed. Finally, the reproducibility during the hypermetabolic phase of all basal factors and their responses to the hormonal manipulation was assessed by studying the same patient on two occasions 8 d apart.
The isotope infusion and blood sampling procedures were as described for protocol 1. However, during the somatostatin infusion period, insulin was also infused at the rate of 0.2-0.3 mU/kg-' * min-'. Plasma glucose concentration was monitored every 10 min and if it fell to 70 mg/dl an infusion of 20% glucose was started at rates ranging from 1.0 to 2.0 mg/ kg-. min-' in order to prevent hypoglycemia.
Analysis ofsamples. Blood samples were collected in ice-cold heparinized tubes and stored on ice until the end of the experiment, when plasma was separated by centrifugation at 4°C. Aliquots of plasma were placed in tubes containing EDTA and trasylol and stored at -20°C for hormone determinations. For the determination of amino acids, aliquots ofplasma were immediately deproteinized with ice-cold 15% sulfosalicylic acid and stored at -20°C for analysis the following day. The rest of the plasma was stored at -20°C to be analyzed later for the isotopic enrichments of glucose and alanine. Amino acid concentrations were determined by column chromatography on an autoanalyzer (121M; Beckman Instruments, Inc., Fullerton, CA). All hormones were determined by radioimmunoassay (RIA). Glucagon was determined as described by Faloona and Unger (16) using Unger's 30K antibody. Insulin was determined with an insulin RIA kit (Amersham Corp., Arlington Heights, IL), cortisol was determined with a cortisol RIA kit (Micromedic Systems, Inc., Horsham, PA), and human growth hormone was determined with an HGH RIA kit (Cambridge Medical Diagnostics, Inc., Billerica, MA). Isotopic enrichment of the plasma glucose was determined on a gas chromatography mass spectrometer (5985B, Hewlett-Packard Co., Palo Alto, CA) (17). To isolate glucose from plasma, plasma proteins were precipitated with BA(OH) and ZnSO4. The supernatant was sequentially passed through beds of anion resin (AG-1-X8) and cation resin (AG-50W-X8) in a chromatography column. The eluant was evaporated to dryness, the penta-acetate derivative was prepared, and the isotopic enrichment measured on the GCMS by selected ion monitoring at massto-change (m/e) 200.1 and 202.1.
The enrichment of alanine was determined on its N-acetyl propyl ester derivative (17). Alanine was separated from the protein-free supernatant of 0.5 ml plasma by desorption with NH4OH from Dowex 50W-X8 200/400 mesh H+ cationic resin, and the NAP derivative was prepared from the dried eluant. The chemical ionization spectrum was used and the ions at m/e 174.2 and 175.2 were selected for monitoring.
Calculations. The rate of endogenous glucose production and alanine flux was calculated according to the Steele equation (18 Figure 3 . Change from basal of plasma insulin and glucagon concentration during a somatostatin (----) and a somatostatin plus insulin infusion (-* -).
During the somatostatin (± insulin) infusion periods both the physiological and isotopic steady states were disrupted. In this situation the non-steady state form ofthe Steele Results Protocol 1. The basal insulin (24±8 gU/mi) and glucagon (486±96 pg/ml) concentrations of this group of patients were significantly elevated (P < 0.01) when compared with the values obtained for normal volunteers. All values for normal postabsorptive subjects were obtained from a control study which employed the same protocols as the present study and was performed concurrently (19) . The somatostatin infusion significantly reduced (P < 0.001) the plasma concentrations of both hormones. There was a mean reduction of 59% in plasma insulin and a 45% reduction in plasma glucagon (Fig. 3 and Table II ). These reductions were less than has been observed in normal volunteers given somatostatin in our control studies and by others (19, 20, 21) . As a result, during somatostatin infusion in burn patients, the insulin level was still within the range ofnormal volunteers, and glucagon remained about two times higher than normal control values (19) . Basal cortisol concentration (35±7 gg/dl) was markedly elevated when compared with the value reported for normal volunteers (4), and was unaffected by the somatostatin infusion. Human growth hormone (2.7±0.5 ng/ ml) was within the normal range, and although somatostatin induced a reduction in its concentration, the change was not significant (Table II) .
The rate of basal glucose production was 3.75±0.5 mg/ kg`. min', which is significantly greater than the value of 2.38±0.07 mg/kg' * min-obtained for normal postabsorptive volunteers (19) . Although somatostatin administration induced a decrease in the rate of glucose production, the magnitude of this change was not statistically significant (Fig. 4) . Similarly, the rate of glucose uptake during the somatostatin infusion, 3.02±0.23 mg/kg-' * min-', was not significantly different from the basal value of 3.35±0.53 mg/kg' * min-'. Basal plasma glucose concentration (115±15 mg/dl) was significantly higher (P < 0.05) than the value (91±2.0 mg/dl) obtained for normal volunteers (19) . There was an initial fall in glucose concentration over the first 20 min of somatostatin infusion, after which it gradually increased. After 90 min, glucose concentration reached a level that was significantly higher than basal (P < 0.01), indicating a reduced clearance ofglucose from plasma (P < 0.05).
( Fig. 4) .
Somatostatin infusion alone caused a significant increase (P < 0.05) in alanine flux 90 min after the infusion started (Fig.  5 ). There was no significant change in alanine clearance rate.
The plasma levels of all nonessential amino acids and three essential amino acids (threonine, methionine, arginine) were *Values were significantly different from basal (P < 0.05).
(P < 0.05) from the basal value of 1,742±154 AM to 2,248±165 AM (Table III) (19) (Table II) . The infusion of somatostatin plus insulin elicited a 30% decrease in glucagon concentration while maintaining basal insulin levels, thereby creating a selective drop in glucagon (Fig. 3) . Cortisol and human growth hormone were again not influenced significantly by somatostatin (+ insulin) infusion (Table II) . The basal glucose production rate (3.71+0.4 mg/kg7' m min-') was almost identical to the rate obtained for the first group of patients, and decreased significantly (P < 0.05) in response to the selective lowering of glucagon (Fig. 4) . The basal value of glucose uptake, 3.5±0.43 mg/kg'* min-', did not change during the selective lowering of glucagon (3.21±0.45 mg/kg-' * min-').
As a consequence, basal glucose concentration (102±12 mg/dl) fell rapidly during the first 20 min of somatostatin plus insulin infusion and exogenous glucose had to be infused in order to maintain the plasma concentration above 70 mg/dl. The rate of glucose clearance remained unchanged throughout the infusion (Fig. 4) .
Alanine flux remained unchanged during the somatostatin plus insulin infusion. Alanine clearance was also unaffected (Fig.  5) . The basal amino acid profile of this group was similar to that ofthe first group (Tables III and IV) . In contrast to the situation when insulin was not replaced, there were no significant changes in the plasma concentrations of any amino acids in response to the somatostatin plus insulin infusion, except for lysine and histidine, whose concentrations increased significantly (P < 0.05). There was no significant change in total plasma amino nitrogen (Table IV) . In order to assess the reproducibility of the response, the same patient was studied according to protocol 2 on postburn days 4 and 12. As shown in Fig. 6 , the responses elicited by the infusion were similar in both studies.
In order to determine if the mode of clinical treatment (excised or nonexcised) had any influence on the observed responses, the study population for each protocol was divided into an excised and a nonexcised group. Comparison of the pooled basal data (Table V) suggested no marked differences, except for a higher basal plasma glucose concentration in the nonexcised group (132±14 vs. 92±5 mg/dl, P = 0.03). The nature and magnitude of response to somatostatin (± insulin) did not differ according to mode of treatment.
Discussion
The primary aim ofthis study was to assess the roles ofglucagon and insulin in mediating the changes in glucose kinetics in severe burn injury. We found that the elevated glucagon concentration was important in stimulating glucose production, and that basal insulin was effective in stimulating basal glucose clearance. In addition, our results suggested that basal insulin was also involved in suppressing glucose production and the release ofamino acids from peripheral tissues, implying that it inhibited protein catabolism.
The results of this study support the role of glucagon as the principal mediator of the increase in basal glucose production, since the lowering of glucagon concentration in both protocols caused a decrease in glucose production. Since an infusion of glucagon into normal man and dog induces only a transient increase in glucose production (24) (25) (26) , it can be argued that the stimulatory effect ofthe hormone is transitory and lacks the ability to cause a sustained increase in glucose production. However, when glucagon is infused in combination with cortisol, the increase in glucose production is sustained (24, 25) . Thus, the simultaneously elevated cortisol level in these burn patients may be responsible for amplifying and sustaining the effect of hyperglucagonemia on glucose production. Although the incomplete suppression ofglucagon by somatostatin in the patients makes it impossible to quantify the exact contribution of glucagon in stimulating glucose production, the fact that even a partial suppression of glucagon elicited a reduction in glucose production strengthens the conclusion that hyperglucagonemia is responsible for stimulating the elevated rate of glucose production even more than ifthe glucagon secretion had been totally suppressed.
The crossover experimental design employed in both protocols enabled us to draw conclusions regarding the role of glucagon, irrespective of the somewhat variable condition of each patient. Thus, our conclusions were not based on comparisons of the values in burn patients with basal values from normal controls, but rather on the direction of change from basal in each patient as a consequence of the hormonal manipulations. Furthermore, intersubject variability was minimized to the extent possible in a group of patients so severely injured. We selected only patients with burns covering >40% of the body surface, since it has been found that the overall metabolic rate (27), as well as glucose kinetics (4), become unrelated to burn size with injuries > 40%. Also, studies have failed to demonstrate marked effects of the days postburn on the response when the range of days was as small as it was in our study (e.g., 4). This was confirmed in the one subject in whom we were able to perform two identical studies, one at day four and one at day 12. There was no difference between the basal kinetic parameters measured, and the response to somatostatin plus insulin administration was similar in both experiments.
Not only do the results ofour study show the role ofglucagon in stimulating basal glucose production, but they indicate a role of basal insulin as an inhibitor of glucose production. Although the lowering of glucagon concentration in both protocols was associated with a decrease in glucose production, the magnitude of the reduction when basal insulin was maintained constant was twice that when basal insulin was allowed to fall. These results are consistent with the finding of Cherrington et al. (28) that an insulin deficiency in normal dogs resulted in a 52% increase in the rate of glucose production, which was abolished when insulin levels were restored to normal. Also, Ward et al. (29) reported that selective insulin deficiency in normal man caused a significant increase in glucose production. It has been shown that low-dose insulin infusions lowered the blood glucose concentration ofinsulin-withdrawn diabetics entirely by reducing glucose production (30) . On the other hand, previous studies have indicated a hepatic insulin resistance in burn injury, in that increases in insulin concentration induced by glucose infusion were not as effective in suppressing glucose production in burned patients as in normal volunteers (4). Apparently, resistance to the action ofincreased levels ofinsulin in burn injury does not imply a lack of normal effectiveness of the basal concentration of the hormone. The role ofbasal insulin as a stimulator ofglucose utilization in these burn patients was established by the significant reduction in glucose clearance during the simultaneous lowering ofinsulin and glucagon, and the maintenance of glucose clearance at the basal level when insulin concentration was maintained. Since the rates ofglucose uptake in the two protocols were comparable (owing to the infusion of glucose in protocol 2), the only interpretation of differences in glucose clearance is that the ability of tissues to take up glucose was greater in the group with the basal insulin level. This finding is in agreement with the results of similar experiments conducted in normal volunteers which have shown that the lowering ofbasal insulin concentration is always accompanied by a significant reduction in glucose uptake, regardless of whether or not glucagon is allowed to fall (20, 26) . It is, however, at odds with the general belief that the reduced glucose tolerance and hyperglycemia ofinjury (particularly during a glucose infusion) is a direct consequence of an inability of insulin to stimulate glucose uptake ("insulin resistance"). Indeed, when burned patients are presented with an exogenous glucose load, although there is an exaggerated insulin response, it is not associated with a corresponding increase in glucose disposal comparable to that of normal volunteers (4, 13, 31) . The decrease in sensitivity to the hypoglycemic action ofinsulin during glucose infusion in those studies led to the conclusion that the elevated rate of basal glucose uptake must be taking place in insulinindependent tissues (4, 13). The current study proves that this is not the case, however, since basal glucose clearance falls when the basal insulin level is reduced. It seems that the diminished responsiveness to insulin in burn injury only becomes evident at high concentrations of insulin.
The elevated alanine flux ofthese burn patients is consistent with the findings of arterio-venous difference studies in which injured patients had an increased peripheral release of amino acids, with alanine accounting for the major increase (6, 32) , and in which injured septic patients had an increase in hepatic alanine uptake (7) . This increased amino acid flux is believed to be a consequence of an accelerated net protein catabolism in peripheral tissues (6, 7, 32) . Results ofthe current study indicate that basal insulin (rather than glucagon) acts to conserve protein by restraining this increased amino acid release, as there was no significant change in alanine flux or in total plasma amino nitrogen when basal insulin concentration was maintained constant. This is consistent with the finding in normal volunteers that declines in plasma amino acid levels after systemic insulinization are due to inhibition of muscle release (22). Since the plasma concentration of amino acids reflect a balance between peripheral tissue release and visceral organ uptake (33) and the uptake of alanine and the essential amino acids leucine, lysine, and valine are not impaired in burn patients (34) , the significantly increased concentration of all plasma amino acids when insulin was reduced, further supports an increased peripheral release due to accelerated net protein catabolism.
Another fact brought to light by the alanine flux data is that glucose production in burn patients is controlled at the liver and not by precursor supply. During the simultaneous lowering of insulin and glucagon concentrations, glucose production decreased despite an increase in the delivery ofalanine to the liver. Thus, although peripheral net protein breakdown and hepatic gluconeogenesis are related, gluconeogenesis is not "driven" by the accelerated rate of net protein breakdown. Furthermore, as indicated by both amino acid concentrations and alanine flux, normalization of alanine production does not necessarily normalize peripheral protein metabolism.
The clinical implication of these findings is that somatostatin may be a useful adjunct to nutritional support in severely burned patients. However, studies of longer duration than 3 h are first necessary to establish that the response we have observed will be sustained, and the effect of hormone manipulation on protein metabolism should be more directly assessed.
